|
High Court Could Review Preemption As Mutual Pharma Petitions
Generic preemption issues may again wind up before the Supreme Court as generic maker Mutual Pharmaceutical is calling on it to reverse an appeals court decision that upheld a $21 million jury award to a patient injured by Mutual’s sulindac.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
PhRMA Joins Generic Makers in Calling for SCOTUS Reversal of Mutual Decision Alabama High Court: Brand Pharmas Can Be Liable for Generics’ LabelingAlabama Supreme Court: Brand Drugmakers Can Be Held Liable for Generic-Drug LabelingAppeals Court: Pharma Off-Label Promotion Protected By First Amendment
|
Subscribe
Archives